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Abstract
Background and Aims
Glycated hemoglobin (HbA1c) is currently used to diagnose diabetes mellitus, while insulin
has been relegated to research. Both, however, may help understanding the metabolic syn-
drome and profiling patients. We examined the association of HbA1c and fasting insulin
with clustering of metabolic syndrome criteria and insulin resistance as two essential char-
acteristics of the metabolic syndrome.
Methods
We used baseline data from 3200 non-diabetic male participants in the Aragon Workers'
Health Study. We conducted analysis to estimate age-adjusted odds ratios (ORs) across
tertiles of HbA1c and insulin. Fasting glucose and Homeostatic model assessment - Insulin
Resistance were used as reference. Here we report the uppermost-to-lowest tertile ORs
(95%CI).
Results
Mean age (SD) was 48.5 (8.8) years and 23% of participants had metabolic syndrome. The
ORs for metabolic syndrome criteria tended to be higher across HbA1c than across glu-
cose, except for high blood pressure. Insulin was associated with the criteria more strongly
than HbA1c and similarly to Homeostatic model assessment - Insulin Resistance (HOMA-
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IR). For metabolic syndrome, the OR of HbA1c was 2.68, of insulin, 11.36, of glucose, 7.03,
and of HOMA-IR, 14.40. For the clustering of 2 or more non-glycemic criteria, the OR of
HbA1c was 2.10, of insulin, 8.94, of glucose, 1.73, and of HOMA-IR, 7.83. All ORs were sta-
tistically significant. The areas under the receiver operating characteristics curves for meta-
bolic syndrome were 0.670 (across HbA1c values) and 0.770 (across insulin values), and,
for insulin resistance, 0.647 (HbA1c) and 0.995 (insulin). Among non-metabolic syndrome
patients, a small insulin elevation identified risk factor clustering.
Conclusions
HbA1c and specially insulin levels were associated with metabolic syndrome criteria, their
clustering, and insulin resistance. Insulin could provide early information in subjects prone
to develop metabolic syndrome.
Introduction
The American Diabetes Association included hemoglobin A1c (HbA1c) as a diagnostic test for
diabetes in their 2010 clinical practice recommendations [1]. In addition to being tightly associ-
ated with diabetes, HbA1c predicts cardiovascular events among non-diabetic individuals and
it may outperform fasting plasma glucose for predicting cardiovascular disease [2]. In contrast,
serum insulin measurement is not used as often, despite the fact that it can identify insulin-
resistant subjects, which is a strong marker of future diabetes [3].
The metabolic syndrome defines a group of cardiovascular risk factors that appear together
and are strongly associated with the development of ischemic heart disease and diabetes [4].
The metabolic syndrome is tightly linked to insulin resistance [5], which is considered one of
its essential characteristics and it was initially required for diagnosis of the syndrome [6].Still,
the clinical criteria that are currently used for diagnosis face numerous limitations [7]. We
hypothesize that HbA1c and insulin measurements, readily available in many clinical settings,
could be used to improve the profiling of patients with metabolic syndrome or subjects prone
to develop it. Previous research has compared HbA1c to glucose and explored the possibility of
substituting HbA1c for the glucose criterion or adding HbA1c as an additional diagnostic crite-
rion [8–13] but no study has compared HbA1c and insulin.
In this study we analyze cross-sectional data from the baseline visit of the AragonWorkers’
Health Study (AWHS) [14] and compare HbA1c and insulin in their association with the met-
abolic syndrome and its traits in non-diabetic individuals. We use risk factor clustering and
insulin resistance as comparison metrics and evaluate their potential for identifying higher
metabolic risk subgroups.
Research Design and Methods
Study population
AWHS (Aragon Workers' Health Study) is a longitudinal cohort study to evaluate cardiovascu-
lar risk factors and subclinical atherosclerosis [14] conducted among workers of the General
Motors assembly factory in Figueruelas (Zaragoza), Spain. All factory workers attending the
annual health exam between February 2009 and May 2010 were invited to participate in the
study, of which 5456 consented to participate (94.5% participation rate). Because of the small
number of women, we restricted the analysis to males (N = 5104) and because relationships
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among our variables of interest were different among diabetic patients we further restricted our
sample to non-diabetic participants (N = 4806), defining diabetes as fasting glucose7 mmol/
L [126 mg/dL], HbA1c6.5%, or being on anti-diabetic medication. Among those, 3392
underwent their laboratory measurements when techniques for both parameters, HbA1c and
insulin, were available. We excluded those with missing data on variables necessary to diagnose
metabolic syndrome (N = 167), or on other relevant covariables such as body mass index
(N = 25). The final sample size was 3200. All participants signed a written informed consent
and the study was approved by the Ethics Committee for Clinical Investigation of Aragon
(CEICA).
Data collection
Data collection was based on clinical interviews, questionnaires, a physical exam, and a fasting
blood draw. Waist circumference was measured at a plane in the midpoint between the ilium
and the costal border with the participant standing. We averaged three blood pressure readings
measured using an automatic oscillometric sphygmomanometer OMRONM10-IT (OMRON
Healthcare Co. Ltd., Kyoto, Japan) with the participant sitting after a 5-min rest.
Peripheral venous blood samples were collected after an 8-hour fasting period. Whole blood
HbA1c was measured by reverse-phase cationic exchange chromatography and double wave-
length colorimetric quantification (Analyzer ADAMS A1c HA-8160, Arkray Factory). Serum
triglycerides, total cholesterol, HDL-cholesterol, and fasting glucose were measured in an
ILAB650 analyzer using the manufacturer’s kits based on spectrophotometric assays. Serum
insulin was measured in an Access 2 analyzer (Beckman Coulter, CA, USA) using a manufac-
turer’s ultrasensitive kit based on a double sandwich immunoassay in frozen samples.
HOMA-IR (Homeostatic model assessment—Insulin Resistance) was calculated as glucose (in
mmol/L) multiplied by insulin (in pmol/L) and divided by 135 [15]. Blood extraction, anthro-
pometric and biochemical measurements were certified with ISO 9001:2008 standards.
Metabolic syndrome and risk factors clustering
Metabolic syndrome was defined according to the 2009 joint interim statement of several inter-
national associations [4], in which subjects must meet at least 3 of the 5 following criteria: high
waist circumference (waist circumference102 cm), high triglycerides (1.7 mmol/L [150
mg/dL] or being on triglycerides lowering medications), low HDL-cholesterol (<1.0 mmol/L
[<40 mg/dL]), high blood pressure (systolic blood pressure 130 mmHg and/or diastolic
blood pressure 85 mmHg or being on antihypertensive medications), and high fasting glu-
cose (5.6 mmol/L [100 mg/dL] or being on drug treatment for elevated glucose).
HbA1c integrates glucose levels over the previous 3 months and insulin is linked with glu-
cose in a biological feed-back loop. In this project, we compared HbA1c and insulin with fast-
ing glucose and HOMA-IR, which also incorporates glucose levels in its formula. Since we
expected that all of these parameters were going to be correlated with glucose levels (one of the
variables used in the definition of the metabolic syndrome), in addition to the metabolic syn-
drome, we also evaluated clusters which do not include fasting glucose: 2-or-more-non-glyce-
mic-criteria and 3-or-more-non-glycemic-criteria defined as the accumulation of, respectively,
2 or3 criteria for metabolic syndrome other than high fasting glucose.
Statistical methods
We evaluated the association of HbA1c and insulin with the presence of the metabolic syn-
drome components and the metabolic syndrome. We also investigated their association with
2-or-more-non-glycemic-criteria, with 3-or-more-non-glycemic-criteria, and with insulin
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resistance, defined as HOMA-IR2.6 [16]. The same associations were studied for fasting glu-
cose and HOMA-IR, which are used as comparison reference parameters.
We divided the sample in HbA1c tertiles (cutoff points at 5.3 and 5.5%) and insulin tertiles
(cutoff points at 26.4 and 42.6 pmol/L [3.8 and 6.1 uU/mL]). Odds ratios (OR) for the presence
and clustering of metabolic syndrome criteria and insulin resistance comparing the higher ter-
tiles of HbA1c and insulin to the lowest tertile were calculated using multivariable logistic
regression adjusted for age (continuous). Tests for linear trend were calculated by including
HbA1c and insulin as continuous variables in the adjusted models. The same calculations for
glycemia and HOMA-IR are provided as reference.
To understand the possible role of body mass index as a confounder on the association of
our studied variables with the individual factors and their clustering we created an additional
model adjusted for BMI, as well as a variable for clustering of non-glycemic-and-non-anthro-
pometric criteria.
We also calculated the receiver operating characteristic curves (ROC curves) for HbA1c and
insulin to evaluate their discrimination ability for detecting metabolic syndrome components,
metabolic syndrome, clusters of non-glycemic components of the metabolic syndrome and
insulin resistance, alongside with those for glycemia and HOMA-IR for comparison.
Using the same HbA1c and insulin cutoffs, we stratified the analysis by presence of meta-
bolic syndrome. As a sensitivity analysis we verified that the estimates did not substantially
change when adjusting them for 5-year-wide age categories instead of continuous-age.
Statistical analyses were performed with R (version 3.0.2) [17] and the plots were created
using the ROCR package (version 1.0–5).
Results
The mean (SD) age of the 3200 non-diabetic men was 48.5 (8.8) years (Table 1). Metabolic syn-
drome was diagnosed in 23.0% of participants and 11.8% were insulin resistant, but only 7.3%
of participants had both metabolic syndrome and insulin resistance. The metabolic syndrome
had 62.0% sensitivity and 82.2% specificity for detecting insulin resistance.
The odds of having metabolic syndrome increased by a factor of 7.16 (95%CI: 5.14, 10.01)
per unit of HbA1c. Glycated hemoglobin (HbA1c) also was associated with HOMA-IR: per
each HbA1c unit increase, HOMA-IR was multiplied by 1.72 (95%CI: 1.60, 1.85). Compared to
participants in the lower tertile of HbA1c, those in the upper tertile had a higher prevalence of
all diagnostic criteria for the metabolic syndrome, their clustering in the metabolic syndrome,
the clustering of factors other than high glucose (2-or-more-non-glycemic-criteria and 3-or-
more-non-glycemic-criteria), and insulin resistance (Table 2). Odds ratios for diagnostic crite-
ria for the metabolic syndrome for HbA1c tended to be higher than those for fasting glucose,
except for high blood pressure. The odds ratios for HbA1c were also higher than those of fast-
ing glucose for non-glycemic-criteria clusters. HbA1c tended to perform better than glucose in
discriminating these conditions, as seen in ROC curves (Figs 1 and 2).
Per each 10 pmol/L (1.4 uU/mL) increase in insulin, the odds for metabolic syndrome
increased by 1.43 (95%CI: 1.38, 1.49). Compared to participants in the lower tertile of insulin,
those in the upper tertile had a higher prevalence of all criteria and clusters, with particularly
strong intensity for high waist circumference (OR 9.13) and for the clusters (Table 2). These
associations were all higher than those for fasting glucose or HbA1c, and tended to be higher
than those for HOMA-IR, except for high blood pressure, which was very similar, and for high
glucose and metabolic syndrome, which tended to be lower. Insulin tended to perform better
than HOMA-IR in discriminating all the criteria of the metabolic syndrome except for high
blood pressure and high glucose, but the latter is linked with HOMA-IR by formula (Fig 1).
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The areas under the ROC curve of HbA1c, insulin, glycemia, and HOMA-IR for metabolic syn-
drome were 0.670, 0.770, 0.754, and 0.796, respectively (Fig 2). For non-glycemic-criteria clus-
ters, the areas under the ROC curve were greater or very similar for insulin than for
HOMA-IR. For the insulin resistance threshold used, insulin was far more relevant than glu-
cose in discriminating insulin resistance, carrying almost all the necessary information (area
under curve 0.995) to discriminate insulin resistance with high sensitivity and specificity (Fig
2).
Among participants with metabolic syndrome (N = 735), high HbA1c was mainly associ-
ated with high glucose and insulin resistance while high insulin was additionally associated
with high waist circumference (Table A in S1 File). In the absence of metabolic syndrome, insu-
lin was more strongly associated than HbA1c to all criteria except high glucose and there were
significant differences between the low- and mid-range of insulin for all criteria except high
blood pressure (Table B in S1 File).
The rank order of the strengths of association of HbA1c, insulin, glucose, and HOMA-IR
with the criteria and clusters remained the same after adjusting the models for body mass
index (Table C in S1 File).
Discussion
In this analysis of non-diabetic male participants from the AWHS study we found that HbA1c
was associated with non-glycemic metabolic syndrome components and their clustering more
closely than glucose. Moreover, insulin outperformed glucose and HbA1c in its association
with the metabolic syndrome, its criteria and clusters of non-glycemic criteria. Prevalence of
various metabolic syndrome criteria increased among participants without metabolic syn-
drome who had even only mild insulin elevation. Finally, insulin alone had a discriminating
Table 1. Characteristics of the study population with and without metabolic syndrome.
Overall Without metabolic syndrome With metabolic syndrome p
N 3200 2465 735
Age (years) 48.5(8.8) 47.5(9.4) 51.8(5.2) <0.001
Body mass index (Kg/m2) 27.5(3.5) 26.6(3.0) 30.6(3.5) <0.001
Waist circumference (cm) 96.7(9.7) 94.1(8.5) 105.6(8.4) <0.001
Total cholesterol (mmol/L) 5.49(0.98) 5.43(0.98) 5.70(0.96) <0.001
Triglycerides (mmol/L) 1.58(1.02) 1.37(0.82) 2.31(1.26) <0.001
HDL-cholesterol (mmol/L) 1.37(0.28) 1.41(0.28) 1.23(0.26) <0.001
LDL-cholesterol (mmol/L)* 3.41(0.83) 3.39(0.83) 3.46(0.80) 0.08
Systolic BP† (mmHg) 126.3(14.3) 124.0(13.2) 134.3(15.0) <0.001
Diastolic BP† (mmHg) 83.3(9.8) 81.4(9.3) 89.8(8.8) <0.001
Fasting glucose (mmol/L) 5.30(0.61) 5.17(0.56) 5.71(0.59) <0.001
HOMA-IR‡ 1.6(1.2) 1.3(0.9) 2.5(1.6) <0.001
Hemoglobin A1c (%) 5.4(0.3) 5.4(0.3) 5.5(0.3) <0.001
Insulin (pmol/L) 39.9(26.5) 34.5(20.9) 58.0(34.2) <0.001
Clinical hypertension (%) 27.6 19.9 53.3 <0.001
Average and standard deviation of clinical, physical, and biochemical parameters. P values were calculated from t-tests.
*n = 3136 due to missing values.
†BP: Blood Pressure.
‡HOMA-IR: Homeostatic Model Assessment—Insulin Resistance.
doi:10.1371/journal.pone.0132244.t001
Glycohemoglobin, Insulin, & Metabolic Syndrome in Males
PLOS ONE | DOI:10.1371/journal.pone.0132244 August 4, 2015 5 / 14
T
ab
le
2.
A
ss
o
ci
at
io
n
o
fH
b
A
1c
,i
n
su
lin
,g
lu
co
se
,a
n
d
H
O
M
A
-I
R
te
rt
ile
s
w
it
h
m
et
ab
o
lic
sy
n
d
ro
m
e
cr
ite
ri
a.
H
b
A
1c
In
su
lin
G
lu
co
se
H
O
M
A
-I
R
*
te
rt
ile
s
te
rt
ile
s
te
rt
ile
s
te
rt
ile
s
(%
)
(p
m
o
l/L
)
(m
m
o
l/L
)
<
5.
3

5.
3
an
d
<
5.
5

5.
5
<
26
.4

26
.4
an
d
<
42
.6

42
.6
<
5.
00

5.
00
an
d
<
5.
55

5.
55
<
1.
02
9

1.
02
9
an
d
<
1.
68
8

1.
68
8
N
95
4
95
3
12
93
10
36
10
93
10
71
95
9
11
55
10
86
10
67
10
66
10
67
A
ve
ra
g
e
5.
08
5.
35
5.
66
19
.3
3
33
.7
1
66
.1
7
4.
61
5.
24
5.
96
0.
73
1.
33
2.
75
H
ig
h
W
ai
st
C
ir
cu
m
f.
(%
)
19
.2
25
.1
37
.3
9.
9
23
.3
51
.0
21
.7
24
.3
38
.2
10
.6
24
.0
50
.1
O
R
†
1.
00
1.
22
1.
98
1.
00
2.
67
9.
13
1.
00
1.
08
1.
82
1.
00
2.
56
7.
90
(R
ef
er
en
ce
)
(0
.9
7,
1.
52
)
(1
.6
2,
2.
43
)
(R
ef
er
en
ce
)
(2
.0
8,
3.
43
)
(7
.2
2,
11
.6
3)
(R
ef
er
en
ce
)
(0
.8
8,
1.
33
)
(1
.4
9,
2.
23
)
(R
ef
er
en
ce
)
(2
.0
1,
3.
27
)
(6
.2
9,
9.
99
)
H
ig
h
T
ri
g
ly
ce
ri
d
.
(%
)
28
.0
29
.7
39
.4
16
.3
31
.1
51
.4
29
.3
32
.6
37
.0
17
.3
30
.6
51
.5
O
R
1.
00
0.
99
1.
44
1.
00
2.
26
5.
25
1.
00
1.
11
1.
23
1.
00
2.
05
4.
80
(R
ef
er
en
ce
)
(0
.8
1,
1.
21
)
(1
.1
9,
1.
74
)
(R
ef
er
en
ce
)
(1
.8
4,
2.
79
)
(4
.2
8,
6.
45
)
(R
ef
er
en
ce
)
(0
.9
2,
1.
34
)
(1
.0
1,
1.
49
)
(R
ef
er
en
ce
)
(1
.6
7,
2.
52
)
(3
.9
3,
5.
87
)
L
o
w
H
D
L
-
ch
o
le
st
.(
%
)
6.
1
8.
5
10
.1
4.
1
6.
5
14
.6
9.
1
8.
1
8.
2
4.
5
7.
1
13
.6
O
R
1.
00
1.
55
1.
97
1.
00
1.
68
4.
18
1.
00
0.
89
0.
93
1.
00
1.
67
3.
53
(R
ef
er
en
ce
)
(1
.0
9,
2.
23
)
(1
.4
0,
2.
79
)
(R
ef
er
en
ce
)
(1
.1
4,
2.
50
)
(2
.9
6,
6.
02
)
(R
ef
er
en
ce
)
(0
.6
5,
1.
21
)
(0
.6
8,
1.
29
)
(R
ef
er
en
ce
)
(1
.1
6,
2.
45
)
(2
.5
2,
5.
01
)
H
ig
h
B
lo
o
d
P
re
ss
u
re
(%
)
42
.3
51
.2
61
.5
41
.6
50
.9
65
.4
42
.2
48
.7
66
.3
40
.7
51
.5
66
.0
O
R
1.
00
1.
10
1.
43
1.
00
1.
37
2.
48
1.
00
1.
16
1.
94
1.
00
1.
45
2.
49
(R
ef
er
en
ce
)
(0
.9
1,
1.
34
)
(1
.1
9,
1.
72
)
(R
ef
er
en
ce
)
(1
.1
5,
1.
64
)
(2
.0
6,
2.
98
)
(R
ef
er
en
ce
)
(0
.9
7,
1.
39
)
(1
.6
1,
2.
35
)
(R
ef
er
en
ce
)
(1
.2
1,
1.
74
)
(2
.0
7,
2.
99
)
H
ig
h
G
lu
co
se
(%
)
18
.7
29
.4
48
.6
20
.2
34
.1
47
.1
–
–
–
13
.6
32
.9
55
.3
O
R
1.
00
1.
50
3.
07
1.
00
1.
98
3.
34
–
–
–
1.
00
3.
02
‡
7.
35
‡
(R
ef
er
en
ce
)
(1
.2
1,
1.
88
)
(2
.5
1,
3.
77
)
(R
ef
er
en
ce
)
(1
.6
2,
2.
43
)
(2
.7
4,
4.
08
)
(R
ef
er
en
ce
)
(2
.4
2,
3.
77
)
(5
.9
3,
9.
16
)
M
et
ab
o
lic
S
yn
d
ro
m
e
(%
)
12
.4
19
.1
33
.6
6.
5
17
.6
44
.4
9.
7
10
.6
47
.9
5.
3
17
.1
46
.5
O
R
1.
00
1.
38
2.
68
1.
00
2.
97
11
.3
6
1.
00
1.
02
‡
7.
03
‡
1.
00
3.
47
‡
14
.4
0‡
(R
ef
er
en
ce
)
(1
.0
7,
1.
79
)
(2
.1
3,
3.
39
)
(R
ef
er
en
ce
)
(2
.2
2,
4.
01
)
(8
.6
5,
15
.1
3)
(R
ef
er
en
ce
)
(0
.7
7,
1.
36
)
(5
.5
0,
9.
06
)
(R
ef
er
en
ce
)
(2
.5
5,
4.
78
)
(1
0.
80
,1
9.
53
)
2+
-n
o
n
-g
ly
c.
-
cr
ite
ri
a
(%
)
26
.0
31
.8
48
.9
15
.3
32
.8
62
.2
29
.5
32
.9
47
.9
16
.4
32
.4
62
.1
O
R
1.
00
1.
12
2.
10
1.
00
2.
61
8.
94
1.
00
1.
08
1.
73
1.
00
2.
34
7.
83
(R
ef
er
en
ce
)
(0
.9
1,
1.
38
)
(1
.7
4,
2.
54
)
(R
ef
er
en
ce
)
(2
.1
1,
3.
24
)
(7
.2
4,
11
.0
9)
(R
ef
er
en
ce
)
(0
.8
9,
1.
30
)
(1
.4
3,
2.
10
)
(R
ef
er
en
ce
)
(1
.9
0,
2.
89
)
(6
.3
8,
9.
65
)
3+
-n
o
n
-g
ly
c.
-
cr
ite
ri
a
(%
)
8.
1
11
.2
17
.0
3.
3
7.
7
26
.7
9.
7
10
.6
17
.4
3.
2
8.
7
26
.0
O
R
1.
00
1.
25
1.
87
1.
00
2.
36
10
.2
0
1.
00
1.
03
1.
62
1.
00
2.
78
9.
84
(R
ef
er
en
ce
)
(0
.9
2,
1.
72
)
(1
.4
2,
2.
50
)
(R
ef
er
en
ce
)
(1
.5
8,
3.
59
)
(7
.1
6,
14
.9
9)
(R
ef
er
en
ce
)
(0
.7
7,
1.
37
)
(1
.2
4,
2.
13
)
(R
ef
er
en
ce
)
(1
.8
7,
4.
21
)
(6
.9
0,
14
.4
8)
In
su
lin
R
es
is
ta
n
ce
(%
)
6.
5
10
.0
16
.9
0.
0
0.
0
35
.1
2.
9
8.
4
23
.1
–
–
–
O
R
1.
00
1.
50
2.
66
–
–
–
‡
1.
00
3.
03
‡
9.
84
‡
–
–
–
(C
on
tin
ue
d
)
Glycohemoglobin, Insulin, & Metabolic Syndrome in Males
PLOS ONE | DOI:10.1371/journal.pone.0132244 August 4, 2015 6 / 14
T
ab
le
2.
(C
on
tin
ue
d
)
H
b
A
1c
In
su
lin
G
lu
co
se
H
O
M
A
-I
R
*
te
rt
ile
s
te
rt
ile
s
te
rt
ile
s
te
rt
ile
s
(%
)
(p
m
o
l/L
)
(m
m
o
l/L
)
<
5.
3

5.
3
an
d
<
5.
5

5.
5
<
26
.4

26
.4
an
d
<
42
.6

42
.6
<
5.
00

5.
00
an
d
<
5.
55

5.
55
<
1.
02
9

1.
02
9
an
d
<
1.
68
8

1.
68
8
(R
ef
er
en
ce
)
(1
.0
7,
2.
11
)
(1
.9
7,
3.
64
)
(R
ef
er
en
ce
)
(2
.0
0,
4.
74
)
(6
.6
4,
15
.1
3)
A
dj
us
te
d
od
ds
ra
tio
s
an
d
th
ei
r
co
nfi
de
nc
e
in
te
rv
al
ca
lc
ul
at
ed
fr
om
a
lo
gi
st
ic
re
gr
es
si
on
m
od
el
ad
ju
st
ed
fo
r
ag
e
(c
on
tin
uo
us
).
A
ll
te
st
s
fo
r
lin
ea
r
tr
en
d,
ca
lc
ul
at
ed
fr
om
m
od
el
s
in
tr
od
uc
in
g
ea
ch
pr
ed
ic
to
r
as
co
nt
in
uo
us
va
ria
bl
e,
w
er
e
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
at
a
le
ve
lα
<
0.
00
1
ex
ce
pt
fo
r
gl
uc
os
e
an
d
hi
gh
tr
ig
ly
ce
rid
es
(p
=
0.
03
)
an
d
fo
r
gl
uc
os
e
an
d
Lo
w
H
D
L-
ch
ol
es
te
ro
l(
p
=
0.
31
).
*H
O
M
A
-I
R
:H
om
eo
st
at
ic
M
od
el
A
ss
es
sm
en
t—
In
su
lin
R
es
is
ta
nc
e.
†
O
R
:O
dd
s
R
at
io
.
‡
O
ut
co
m
e
va
ria
bl
e
di
re
ct
ly
re
la
te
d
to
th
e
pr
ed
ic
to
r
be
ca
us
e
of
a
fo
rm
ul
a
or
be
ca
us
e
of
a
di
ag
no
st
ic
cr
ite
rio
n.
do
i:1
0.
13
71
/jo
ur
na
l.p
on
e.
01
32
24
4.
t0
02
Glycohemoglobin, Insulin, & Metabolic Syndrome in Males
PLOS ONE | DOI:10.1371/journal.pone.0132244 August 4, 2015 7 / 14
Fig 1. ROC curves of HbA1c, insulin, glycemia and HOMA-IR for metabolic syndrome criteria.ROC
curves for detecting individually each metabolic syndrome criteria. The small circles indicate the sensitivity
and specificity when using the tertiles of each variable as cut-offs. For high glucose, the glycemia curve can
not be seen as it lies exactly at the left and upper borders.
doi:10.1371/journal.pone.0132244.g001
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ability similar to that of HOMA-IR, indicating that glucose contributes little information to the
HOMA-IR formula in contexts similar to our population.
HbA1c is a product of non-enzymatic glycosylation that reflects the average glucose over
the preceding weeks [18]. HbA1c measurement does not require fasting and is highly standard-
ized and widely available nowadays [1]. Insulin measurement has a similar cost, but its use has
been confined to the clinical diagnosis of selected endocrine conditions, like insulinomas [19],
and to the measurement of insulin resistance [20], mostly for research purposes. Current clini-
cal guidelines discourage measuring insulin concentration in the assessment of cardiometabolic
Fig 2. ROC curves of HbA1c, insulin, glycemia and HOMA-IR for insulin resistance and criteria clusters. ROC curves for detecting insulin resistance,
the metabolic syndrome, 2 or more, and 3 or more criteria for the metabolic syndrome other than the high glucose criterion. The small circles indicate the
sensitivity and specificity when using the tertiles of each variable as cut-offs. For insulin resistance, the HOMA-IR curve can not be seen as it lies exactly at
the left and upper borders.
doi:10.1371/journal.pone.0132244.g002
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risk, because knowledge of this value does not alter patient management in a prevention
scheme that focuses in treatment of high-risk patients [19], in spite of the strong known inde-
pendent association of insulin with ischemic heart disease [21]. Insulin assays are still in a pro-
cess of standardization [22] and fasting blood samples are needed to calculate HOMA-IR [23].
HbA1c was associated with high waist circumference, high triglycerides, and low HDL-cho-
lesterol more closely than glucose in our results. Succurro et al. had also reported a better corre-
lation of HbA1c with measures of visceral obesity, HDL-cholesterol, and triglycerides [8]. Like
in our study, in Sucurro et al.’s analyses, glucose correlated better than HbA1c with systolic
blood pressure and pulse pressure, suggesting that different pathophysiological pathways
underlie the clustering of blood pressure with other metabolic parameters. Indeed, the complex
pathophysiology of the metabolic syndrome conveys separate vasomotor and lipid pathways
[5]. Hence, it is important to know which aspects of the syndrome are captured by glucose,
which by HbA1c, and which by insulin. HbA1c is a better predictor than glucose for atheroscle-
rotic events [2], which are strongly linked to lipid metabolism [24]. Furthermore, flow-medi-
ated dilation, a measurement of endothelial dysfunction recognized as an early stage of
atherosclerosis, is more strongly associated with HbA1c than with glucose [25]. We found that
insulin was strongly associated to all traits individually more intensely than HbA1c and glucose
and, in particular, to abdominal obesity. The metabolic syndrome was linked to insulin resis-
tance since the concept was introduced. Interestingly, our results show that insulin alone was
similarly or more strongly associated than HOMA-IR to all the traits excluding high glucose,
which is included in the HOMA-IR formula.
Using HbA1c to identify metabolic syndrome patients yielded 0.670 as the area under ROC
curve. Our result is similar to 0.678, previously reported by Succurro et al. [8], and 0.648, previ-
ously reported by Sung et al. [9], and greater than 0.602, reported by Dilley et al. [26]. The area
under curve that we found for insulin, 0.770, was greater than that for HbA1c.
Some researchers have tried to substitute HbA1c for the glucose metabolic syndrome crite-
rion or to add HbA1c as an additional diagnostic criterion [8,10–13]. Succurro et al.[8] pointed
out that, in their analysis, the metabolic syndrome using an HbA1c criterion instead of glucose
performed worse in detecting some subjects who still had an unfavorable cardiometabolic risk
profile. Using the current definition of the metabolic syndrome (which includes glucose) as
standard to compare the glucose criterion with criteria based on other measurements is incon-
clusive. In the absence of a clinical gold-standard, measurements that are closer to the syn-
drome pathophysiology should be used to evaluate diagnostic performance improvements:
Clustering may reflect an underlying common mechanism for the different traits and insulin
resistance has been often used as gold-standard for the metabolic syndrome. HbA1c and espe-
cially insulin were more strongly associated to clusters of non-glycemic metabolic traits than
glucose. Insulin seems to be a good marker for a common underlying mechanism, very similar
to HOMA-IR, and HbA1c still seems to be a better marker than glucose. Insulin alone showed
a high accuracy for defining insulin resistance in this range of values whereas glucose played a
minor role in the HOMA-IR variation. This fact has been known for long [27] but it is very
often overlooked. Consequently, if a laboratory measurement was to be considered to be added
to the metabolic syndrome criteria, our findings and other pathophysiologic arguments would
favor adding insulin over HbA1c, as it was proposed in the initial WHO definitions of the met-
abolic syndrome [6].
In this otherwise-healthy population, with some overweight but not severe obesity, insulin
seems to capture an earlier stage of cardiometabolic disorders than HbA1c and glucose. Insulin
appears to be an early marker of metabolic derailment which could identify stages at which cor-
rection of lifestyle might require subtler and thus easier modifications than in complete meta-
bolic syndrome patients. This conditions may be missed if only glucose is monitored, as
Glycohemoglobin, Insulin, & Metabolic Syndrome in Males
PLOS ONE | DOI:10.1371/journal.pone.0132244 August 4, 2015 10 / 14
elevation in the fasting period only occur when many other disorders, mainly lipid changes,
but probably also hemodynamic, have already taken place. Although insulin measurement
does not add discriminative capacity to the metabolic syndrome as a predictor for future diabe-
tes in the general population [28], our results suggest that it might be better than HbA1c and
glucose in detecting the initial clustering of cardiovascular risk factors even with small insulin
elevations. HbA1c, being a glucose-related measurement does not help shortening the time to
detection.
In a non-selected population, an HbA1c in the higher normal range can trigger a search for
other cardiometabolic risk factors and induce screening for metabolic syndrome criteria. With
a similar cost, however, fasting insulin provides a measurement that may be more closely
linked to the pathways conducing to the metabolic syndrome. Given that type 2 diabetes is part
of a continuum in which cardiovascular events are among the most severe complications, insu-
lin or insulin resistance may be more valuable measurements in asymptomatic patients than
HbA1c for assessing the degree of metabolic impairment [29]. Furthermore, fasting serum
insulin can be used as a surrogate of insulin resistance in epidemiological studies [3] particu-
larly among non-diabetic subjects [30].
Nowadays, insulin measurements are used mainly for research purposes [22], insulin is not
included in the current definitions of metabolic syndrome or diabetes, despite the fact that
many studies documented the association of increased levels of insulin to clustering of cardio-
vascular risk factors and it was used to define insulin resistance in the initial definitions of the
metabolic syndrome[31–35]. Our findings show that insulin could be used as biomarker for
cardiovascular risk factors development yielding more information than glucose levels. Conse-
quently, new clinical applications for insulin could be considered and tested. Still, in spite of
the promising advantages of insulin that we found, it is early to recommend its use in the clini-
cal setting. Clinical studies should be performed, testing its usefulness for early diagnosis of car-
diovascular and metabolic risk and subsequent preventive care. These studies should focus on
its role in the prevention of the development of diabetes, by detecting pre-diabetic conditions
and hard cardiovascular outcomes, by detecting early risk factors clustering. This would pave
the way for insulin to have clinical utility as an early biomarker in primary preventive care
settings.
The strengths of this study include the size of a cohort of well characterized participants
using high quality procedures including blood extraction, anthropometric and biochemical
measurements certified with ISO 9001:2008 standards. Among its limitations, the sample was
restricted to working white male participants and the results might not apply to other popula-
tions. Additionally, they only apply to non-diabetic people. We excluded participants with dia-
betes because among those receiving antidiabetic medications, both main parameters
considered, HbA1c and insulin, would be altered depending on their treatment and also
because, among untreated diabetic patients, the linearity of the relationship between HbA1c
and other parameters disappears, which would have led to biased estimates had we included
them. The availability of HbA1c and insulin measurements in the laboratory started and ended
at different dates for each parameter, which caused that in one third of our participants they
did not overlap. Given that the dates and order of the participants attending their annual
checkup can be considered random and unrelated to their health status the resulting subsample
cannot be considered to be biased or to have a reduced representativeness. We also used a
cross-sectional design and thus no temporal criterion of causation can be inferred for these
associations. Finally, we used a single measurement of cardiometabolic parameters subject to
within personal variability and laboratory measurement error, which may attenuate the
observed associations.
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Conclusions
In summary, HbA1c and insulin measurements were highly associated with metabolic syn-
drome traits. HbA1c is more readily available than insulin and outperforms glucose in terms of
association with risk factors, clusters and cardiovascular risk. Fasting insulin is an important
measurement for evaluating metabolic risk in research studies and it may be even more infor-
mative than HbA1c. Insulin could provide early information in subjects prone to develop met-
abolic syndrome.
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